FibroGenesis, is a regenerative medicine company developing an innovative regenerative medicine solution for chronic diseases using fibroblasts.
FibroGenesis is undertaking an accelerated preclinical program to find a cure for COVID-19 Acute Respiratory Distress Syndrome (ARDS) using its advanced fibroblast cell therapy.
Multi-Pronged Attack on COVID-19:
FibroMune™ and PneumoBlast™
We are developing two products for treatment of COVID-19. The first, FibroMune™, is comprised of conditioned media from activated fibroblasts, which induces interferon beta production when administered. FibroMune™ is being developed to activate innate immunity in order to prevent virus propagation. PneumoBlast™ is comprised of proprietary “universal donor” fibroblasts for the treatment of acute respiratory distress syndrome (ARDS), which is the main cause of COVID-19 mortality.
October 8, 2020
FibroGenesis Named #2 Most Innovative Company of 2020
October 1, 2020
FibroGenesis Announces Collaboration Agreement with Brazilian Biotech R4D Read More
September 28, 2020
FibroGenesis Announces Manufacturing Agreement Read More
August 12, 2020
FibroGenesis Reports Breakthrough in Prevention of COVID-19 Blood Clotting Read More
July 21, 2020
FibroGenesis Reduces COVID-19 Lung Scarring in Animal Model Read More
July 1, 2020
FibroGenesis Identifies Mechanism Responsible for Blocking COVID-19 Lung Inflammation Read More
Currently, FibroGenesis holds 240 U.S. and international issued patents issued/pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson’s, Chronic Traumatic Encephalopathy, Colitis, Cancer, Diabetes, Liver Failure and Heart Failure. FibroGenesis represents the next generation of medical advancement in cell therapy.